Results 221 to 230 of about 320,703 (320)

The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Blood, 2014
Min Lu, Lijuan Xia, Yan Li, Xiaoli Wang, R. Hoffman   +4 more
semanticscholar   +1 more source

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment. [PDF]

Virol J
Zhang W, Chen J, Sun W, Xie N, Tian F, Ruan Q, Song J.   +6 more
europepmc   +1 more source

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks. [PDF]

Hepatol Int
Tan Z, Kong N, Zhang Q, Gao X, Shang J, Geng J, You R, Wang T, Guo Y, Wu X, Zhang W, Qu L, Zhang F.   +12 more
europepmc   +1 more source

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

, 2019
John Mascarenhas, Heidi Kosiorek, Josef T. Prchal, Abdulraheem Yacoub, Dmitry Berenzon, Maria R. Baer, Ellen K. Ritchie, Richard T. Silver, Craig M. Kessler, E. F. Winton, Maria Chiara Finazzi, Alessandro Rambaldi, Alessandro M. Vannucchi, D Leibowitz, Damiano Rondelli, Murat O. Arcasoy, Rosalind Catchatourian, Joseph Vadakara, Vittorio Rosti, Elizabeth O. Hexner, Marina Kremyanskaya, Lonette Sandy, Joseph Tripodi, Vesna Najfeld, Noushin Farnoud, Mohamad E. Salama, Rona Singer Weinberg, Raajit K. Rampal, Judith D. Goldberg, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman   +31 more
openalex   +2 more sources

A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data. [PDF]

Virol J
Ye YM, Lin Y, Sun F, Yang WY, Zhou L, Lin C, Pan C.   +6 more
europepmc   +1 more source

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. [PDF]

Blood Adv
Sørensen AL, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Rahbek Gjerdrum LM, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, Hasselbalch H.   +13 more
europepmc   +1 more source

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report

, 2019
Bogdan Augustin Chiş, Cristina Nicula, Dan L. Dumitraşcu   +2 more
openalex   +2 more sources

Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis. [PDF]

BMC Infect Dis
Xu S, Ye XT, Zhang D, Dong P, Wu YH, Pan CW.   +5 more
europepmc   +1 more source

Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. [PDF]

Front Med (Lausanne)
Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y.   +5 more
europepmc   +1 more source

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D. [PDF]

Trop Med Infect Dis
Gherlan GS, Lazar SD, Culinescu A, Smadu D, Vatafu AR, Popescu CP, Florescu SA, Ceausu E, Calistru PI.   +8 more
europepmc   +1 more source